(Un)common sense in oncology, DOACs in device-detected AF, and hypertension in the elderly

In this podcast recorded in early September, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the October issue of DTB. They discuss the editorial that highlights the work of the Common Sense in Oncology movement and its aim "to counteract the trend towards irrational, industry-designed, profit-driven cancer drug development" - . They talk about the results of a systematic review and meta-analysis of two randomised controlled trials that assessed the effect of treating people who have device-detected subclinical atrial fibrillation (AF) with a direct oral anticoagulant - . The main article discusses the management of hypertension in older people - . They begin by highlighting an article* that considers the challenges associated with the introduction of new drugs for the treatment of Alzheimer's disease. *Walsh S, Merrick R, Milne R, et al. Considering challenges for the new Alzheimer's drugs: clinical, population, and health system perspectives. Alzheimers Dement. 2024. doi: 10.1002/alz.14108. [Epub ahead of print 4 Aug 2024]. Please

You can listen to (Un)common sense in oncology, DOACs in device-detected AF, and hypertension in the elderly online on Radio and Podcast. Open the player on this page to stream the available audio.

(Un)common sense in oncology, DOACs in device-detected AF, and hypertension in the elderly is an episode from DTB podcast by BMJ Group.

This episode is 19:49 long.

This episode was published on Sep 25, 2024.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from DTB podcast when more episodes are available from the podcast feed.